Prevention and Management of Tardive Dyskinesia
Abstract
Because no adequate therapy is available, the prevention of tardive dyskinesia is of great importance. The disorder may be prevented by periodic evaluations of the neurologic status of patients on long-term drug treatment, followed by reducing the drug dosage or discontinuing administration. Withdrawing neuroleptics, particularly in patients with pseudoparkinsonism, may uncover latent dyskinesia. For patients already exhibiting this disorder, the use of small doses of neuroleptics may be safe, provided changes in neurological symptoms are monitored carefully.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
